193 related articles for article (PubMed ID: 14716744)
1. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
Kristiansen G; Pilarsky C; Pervan J; Stürzebecher B; Stephan C; Jung K; Loening S; Rosenthal A; Dietel M
Prostate; 2004 Feb; 58(2):183-92. PubMed ID: 14716744
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
4. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
5. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
6. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
7. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
Xu C; Jung M; Burkhardt M; Stephan C; Schnorr D; Loening S; Jung K; Dietel M; Kristiansen G
Prostate; 2005 Feb; 62(3):224-32. PubMed ID: 15389793
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
[TBL] [Abstract][Full Text] [Related]
9. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma.
Sano A; Kato H; Sakurai S; Sakai M; Tanaka N; Inose T; Saito K; Sohda M; Nakajima M; Nakajima T; Kuwano H
Ann Surg Oncol; 2009 Feb; 16(2):506-14. PubMed ID: 19050962
[TBL] [Abstract][Full Text] [Related]
10. CD24 expression is a new prognostic marker in breast cancer.
Kristiansen G; Winzer KJ; Mayordomo E; Bellach J; Schlüns K; Denkert C; Dahl E; Pilarsky C; Altevogt P; Guski H; Dietel M
Clin Cancer Res; 2003 Oct; 9(13):4906-13. PubMed ID: 14581365
[TBL] [Abstract][Full Text] [Related]
11. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
12. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases.
Banyard J; Bao L; Hofer MD; Zurakowski D; Spivey KA; Feldman AS; Hutchinson LM; Kuefer R; Rubin MA; Zetter BR
Clin Cancer Res; 2007 May; 13(9):2634-42. PubMed ID: 17473194
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.
Weichert W; Denkert C; Burkhardt M; Gansukh T; Bellach J; Altevogt P; Dietel M; Kristiansen G
Clin Cancer Res; 2005 Sep; 11(18):6574-81. PubMed ID: 16166435
[TBL] [Abstract][Full Text] [Related]
14. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
[TBL] [Abstract][Full Text] [Related]
15. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
17. Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables.
Ferrari MK; McNeal JE; Malhotra SM; Brooks JD
Urology; 2004 Oct; 64(4):749-53. PubMed ID: 15491714
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
Chou YY; Jeng YM; Lee TT; Hu FC; Kao HL; Lin WC; Lai PL; Hu RH; Yuan RH
Ann Surg Oncol; 2007 Oct; 14(10):2748-58. PubMed ID: 17680316
[TBL] [Abstract][Full Text] [Related]
19. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung.
Ikeda J; Oda T; Inoue M; Uekita T; Sakai R; Okumura M; Aozasa K; Morii E
Cancer Sci; 2009 Mar; 100(3):429-33. PubMed ID: 19077003
[TBL] [Abstract][Full Text] [Related]
20. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
